Type 2 Diabetes

Analysis of data from the SOS study indicates bariatric surgery was associated with a 37% reduction in incident cancer among individuals with obesity and diabetes versus conventional obesity treatments, with those achieving diabetes remission experiencing a 60% reduction in risk.

After a weekend of discussions and presentations, Endocrinology Network's editorial staff has compiled a list of 6 noteworthy posters presented at TMIOA's 19th annual WCIRDC.

Fish oil intervention and DASH diet show no statistically significant effect on glycemic control and adiposity.

With TMIOA hosting the 19th Annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease, the Endocrinology Network editorial staff has compiled a list of 5 noteworthy posters presented at the conference.

Participants with diabetes mellitus specifically were more prone to develop insulin resistance due to BPA exposure as compared to non-diabetic participants

A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.

A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.

Of the 416 basal insulin initiators, only one-third of them reached the appropriate fasting blood glucose level.

Dr. Zeitler highlights the long-term microvascular risk complications observed in T2D patients in the TODAY2 observational study.

These reductions, investigators noted, were slightly greatest yet not statistically significant.

The DCRM Task Force recommendations were described as first-of-its-kind guidance for patients with overlapping diabetic, cardiorenal and metabolic disease.

Expert clinicians discuss insulin therapy for treating type 2 diabetes and comment on what to look forward to in the future of diabetes care.

Drs Dennis Bruemmer and Jennifer Green review recent trial data on a novel combination of GIP and GLP1 receptor agonists to treat type 2 diabetes.

A Mayo Clinic-led retrospective analysis suggests patients with T2D had an 88% greater risk of developing any diabetic retinopathy within the first 15 years of diagnosis compared to those with T1D.

Patients with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis and significantly improved insulin sensitivity versus conventional therapy.

The team estimated the time to individual plasma glucose recovery following exposure to the medication.

Data show the age-adjusted prevalence of hyperinsulinemia in adults without diabetes increased by 18% in the study population between 1999 - 2000 and 2017 - 2018.

In keeping with earlier data, investigators suggested that metabolic syndrome was associated with severe cases of infection.

Data from a secondary analysis of the PREDICT 1 trial provides insight into the effects of sleep habits on postprandial glucose control among a cohort of healthy individuals.

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.